A breast cancer 3D model derived from tissue biopsies
- Conditions
- Breast Cancer
- Registration Number
- NL-OMON21020
- Lead Sponsor
- Maastricht University Medical Center +
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
Female,
->18 years,
Exclusion Criteria
-Physically or mentally incapable or incompetent to sign informed consent.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To develop a patient derived clinical model of breast (cancer) organoids using tissue biopsies.
- Secondary Outcome Measures
Name Time Method Histological, genomic, and proteomic analysis will be conducted to provide insight in whether these organoids are patient representative and could result in patient tailored treatment. Furthermore, existing and newly developed therapies will be tested on this model - with the ultimate goal, to predict therapy response and/or resistance. Therapy efficacy will be assessed using viability assays, and genomic- and proteomic analysis.